The development of the first drug-like selective angiotensin II type 2 (AT 2 ) receptor agonist (22) derived from the non-selective angiotensin II type 1 (AT 1 ) receptor/AT 2 receptor agonist L-162,313 is presented. Compound 22 with a K i value of 0.4 nM for the AT 2 receptor and a K i > 10 mM for the AT 1 receptor induces outgrowth of neurite cells, stimulates p42/p44 mapk , enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats and lowers the mean arterial blood pressure in anaesthetised spontaneously hypertensive rats. Thus, the peptidomimetic 22 exerts a similar biological response as the endogenous peptide angiotensin II after selective activation of the AT 2 receptor. In addition, Compound 22 has a bioavailability of 20-30% after oral administration and a half-life estimated to four hours in the rat. Compound 22 will therefore serve as a valuable research tool enabling studies of the function of the AT 2 receptor in more detail.
Introduction
Selective angiotensin II (Ang II) type 1 (AT 1 ) receptor antagonists block well-known functional effects of the octapeptide Ang II, such as vasoconstriction, aldosterone release and cardiovascular growth. [1] [2] [3] [4] [5] [6] [7] [8] Losartan was the first selective AT 1 receptor antagonist to reach the market, followed by candesartan and valsartan (figure 1). [9] [10] [11] With the discovery of a second Ang II receptor type (AT 2 ), the focus turned towards this receptor in the development of new drugs. Due to the low levels of expression of the AT 2 receptor, lack of good in vitro models and model compounds, the role of the AT 2 receptor has been difficult to elucidate. With the limited knowledge of the role of the AT 2 receptor, drug development programmes focused initially on developing balanced AT 1 /AT 2 receptor antagonists. Several balanced AT 1 /AT 2 receptor antagonists and some compounds with selectivity towards the AT 2 receptor (figure 2) were obtained in these programmes. [12] [13] [14] None of these compounds seemed to have an improved effect compared to the selective AT 1 receptor antagonist. During the development of balanced AT 1 /AT 2 receptor antagonists, it was discovered that the Merck compound L-162,313 (AT 1 receptor K i : 3.9 nM; AT 2 receptor K i : 2.8 nM) acted as an agonist on the AT 1 receptor (figure 3). 15, 16 With increased knowledge of the role of the AT 2 receptor, it was found that activation of the AT 2 receptor exhibits effects that could be considered more 'anti-AT 1 pressure, inhibits cell proliferation, induces programmed cell death and extracellular matrix remodelling, as well as axonal regeneration. 1, [17] [18] [19] [20] [21] Moreover, AT 2 receptor expression is upregulated in pathological conditions such as heart failure, renal failure, myocardial infarction, brain lesions, vascular injury and wound healing. 1, [22] [23] [24] In addition, it has been demonstrated that activation of the AT 2 receptor stimulates alkaline secretion by the duodenal mucosa in rats. 25 Thus, it was highly attractive to obtain a selective AT 2 receptor agonist for further studies of the effects of AT 2 receptor stimulation and possibly develop a new drug class.
As a starting point, we turned our focus on the compound L-162,313 that was shown to exhibit an agonistic effect on the AT 1 receptor. Since L-162,313 showed similar affinity for both the AT 1 and the AT 2 receptor, our hypothesis was that L-162,313 would act as an agonist at the AT 2 receptor as well. With the duodenal mucosal alkaline secretion in rats as our in vivo model, 25 we were able to determine that L-162,313 indeed showed an agonistic effect on the AT 2 receptor. 26 This result encouraged us to start a development programme to obtain a selective AT 2 receptor agonist.
Modification of L-162,313
From the literature it was known that removal of a methyl group from L-162,782, an agonist closely structurally related to L-162,313, provided L-162,389 which was found to act as an antagonist at the AT 1 receptor in vivo (figure 4). 27 Thus, a subtle molecular alteration was shown to determine the agonist/antagonist properties of these ligands. The three compounds described above were all essentially equipotent as AT 1 /AT 2 receptor-binding ligands, but by replacing the alkyl group with a m-methoxybenzyl group an agonist, L-163,491, with an approximately 70-fold selectivity for the AT 1 receptor subtype, was obtained. 28 With this knowledge of the sensitivity of the isobutyl group towards minor alteration, we focused our modifications of L-162,313 to other parts of the molecule.
Sulphonamide modification
The most accessible position to modify from a synthetic point of view, is the sulphonamide side chain. As apparent from table 1, all variations of the butyloxy group investigated were deleterious with respect to AT 2 receptor affinity, although moderate AT 2 receptor affinity was encountered by shortening of the side chain by removal of the Paper SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore oxygen atom (Compound 6). Notably, the ethyloxy derivative 1 exhibited no detectable AT 2 receptor affinity. The lack of AT 2 receptor affinity exhibited by 4 is also somewhat remarkable considering the previous results by Mantlo et al., 29 where a higher AT 2 receptor selectivity was observed for compounds bearing the cyclopentyl side chain. With regard to AT 1 receptor affinity, the impact of alterations to the butyloxy side chain was considerably less pronounced. All compounds bound, in varying degrees, to the AT 1 receptor. Thus, the effect caused by alterations of the butyloxycarbonylsul-phonamide portion of L-162,313 seemed to resemble the outcome of variations of the isobutyl group in the 5-position, as reported by Kevin et al., 30 in that even the small structural modifications performed tended to reduce AT 2 receptor affinity while retaining AT 1 receptor affinity.
Modification of the benzylic heterocycle
The data in series A with the sulphonamide modifications and previous findings 27 suggested 
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Structurally-related compounds to L-162,313. that the 2-(N-butyloxycarbonyl)sulphonamide and 5-isobutyl might be compulsory for good AT 2 receptor affinity. We therefore turned our attention towards modifications of the bicyclic upper part of the molecule in the hope of improving the AT 2 /AT 1 receptor selectivity. We hypothesised that the lower part of L-162,313 might be pivotal for agonism, while a proper upper heterocyclic moiety could conceivably provide high AT 2 receptor selectivity. We were particularly interested in a series of AT 2 receptor ligands of the biaryl type reported by Glinka et al. 31 Some of these compounds exhibited an impressive AT 2 / AT 1 receptor selectivity (e.g. for one of the derivatives, AT 1 receptor: K i > 3,000 nM and AT 2 receptor: K i = 0.06 nM). The compounds were comprised of a quinazolin-4-one scaffold substituted in the 6-position with, for example, a variety of acylamido groups. Guided by the results of Glinka et al., 31 the compounds in table 2 were designed and synthesised.
From table 2 it is apparent that the substituent in the 6-position of the quinazolinones can significantly affect the selectivity. While all amides (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) bind to the AT 1 receptor, albeit weakly, minor structural variations could have a dramatic influence on the affinity to the AT 2 receptor. The thiophene and the corresponding benzene rings in L-162,313 and L-162,782, respectively, act as true bioisosteres, but these aromatic nuclei are not necessarily interchangeable when constituting a part of the 6-substituent of the quinazolinone moiety. A comparison of the tertiary ethyl amides 12 and 13 suggests that interchanging the two aromatic systems has no large impact on the binding affinity to the AT 2 receptor. However, substitutions of the ethyl group of the thiophene derivative 13 with either hydrogen (cf. 13 and 10) or a benzyl group (cf. 13 and 17) are deleterious for AT 2 receptor affinity. However, when the benzene analogue 12 was subjected to the same modifications, surprisingly, the affinity was largely retained (cf. 12, 9 and 16). These results are difficult to rationalise but demonstrate a complex structure-activity relationship of the compounds in series B. Thus, as in series A where the AT 2 receptor affinity quinazolinone Compound 8 at concentrations 1-100 µM was observed in the rat duodenum, suggesting that 8, contrary to L-162,313, does not act as an AT 2 receptor agonist under these test conditions. Although, we cannot rule out that the lack of agonistic effect of Compound 8 in the rat is attributed to the fact that affinity to the AT 2 receptor in porcine membrane may not be translated to the rat AT 2 receptor.
Structural simplification of L-162,313
From the quinazolinone series we could draw the conclusion that modification to this part of the molecule could indeed render more AT 2 receptor-selective compounds. We therefore hypothesised that if we could simplify the structure of L-162,313, to obtain a more water soluble starting scaffold, we could in a later stage decorate the scaffold with substituents to obtain selectivity towards the AT 2 receptor and hopefully maintain the better solubility properties. We therefore designed a series of compounds where we reduced the original heterocycle of L-162,313 stepwise.
As apparent from table 3, removal of the alkyl groups from the bicyclic heterocycle resulted in a dramatic loss of affinity to the AT 1 receptor, while the AT 2 receptor affinity was only slightly affected (Compound 18). A similar response was encountered after replacement of the imidazopyridine with a 2-ethyl-1H-benzimidazole (Compound 19) . Unexpectedly, the AT 1 receptor affinity was increased by the removal of the ethyl group from the benzimidazole (Compound 20) . Notably, with 2-methylimidazole or imidazole (Compounds 21 and 22) as heterocycles, the affinity to the AT 1 receptor remained poor but a 10-fold improvement of the AT 2 receptor affinity was observed. On the other hand, further simplification of the structure, i.e. changing from an imidazole to a nitrile (Compound 23) led to a 100-fold improved AT 1 receptor affinity, while the affinity to the AT 2 receptor now dropped more than 100-fold. Thus, this alteration delivered a non-selective ligand. Removal of the benzylic methylene group of 23 resulted in the inactive arylnitrile 24. Furthermore, employing a benzylthiophene instead of a phenylthiophene scaffold, in combination with attachment of the imidazole directly to the aromatic ring had a deleterious effect on the affinities (Compound 26). Compound 22, with the highest affinity and receptor selectivity, was chosen for further in vitro and in vivo studies.
To study the effects of Compound 22 on differentiation, we used NG108-15 cells. In their undifferentiated state, neuroblastoma × glioma hybrid NG108-15 cells have a rounded shape and divide actively. It has been shown previously that these cells express only the AT 2 receptor, 32, 33 and that a three-day treatment with Ang II or the selective peptidic AT 2 receptor agonist CGP42112 induces neurite outgrowth. 33 The mechanisms involve a sustained increase in p42/p44 mapk activity 34 and activation of the nitric oxide/guanylyl cyclase/ cGMP pathway. 35 In vitro morphological effects induced by Compound 22 in NG108-15 cells After a three-day treatment with 22 (0.1 mM), most cells extended one or two neurite processes, while the cell body retained a rounded appearance. When compared to Ang II (0.1 mM), Compound 22 induces the same morphological changes, with the longer processes exhibiting a growth cone at the tip. 33 This effect was mediated through the AT 2 receptor, since co-incubation of 22 with the AT 2 receptor antagonist, PD 123,319 (1 mM), virtually halted neurite elongation, while alone, PD 123,319 did not alter the morphology of the untreated cells. Quantification of these results indicated that a three-day treatment with 22 increased the number of cells with neurites (from 5.5±0.4% in control cells to 15.6±0.7% in Ang II-treated cells and 19.9±1.1% in the Compound 22-treated cells). This effect was abolished in cells co-incubated with PD 123,319 (figure 5).
To further explore if Compound 22 shares the same signalling transduction as Ang II, 34, 35 cells were pre-incubated for three days with 10 mM PD 98,059; a dose that abolished MAPK activity. Alone, PD 98,059 induced a rounding up appearance of the cell body, and when co-incubated with 22, a decreased length and number of neurites was also observed. Cells were also pre-incubated with LY-83,583 (0.5 mM), an inhibitor of soluble guanylyl cyclase, or with KT 5823 (1 mM), an inhibitor of cGMP-dependent protein kinases, which were added every day, 30 minutes before Compound 22. Alone, KT 5823-and LY-83,583-treated cells had the same morphological appearance as the untreated control cells.
However, cells co-incubated with 22 and LY-83,583 or KT 5823 had only one or two thin processes. Quantification of these results (figure 6) indicated that a three-day treatment with 22 increased the number of cells with neurites (from 5.5±0.4% in control cells to 15.6±0.7% in Ang II-treated cells and 19.9±1.1% in the Compound 22-treated cells). This effect was abolished in cells co-incubated with PD 98,059, LY-83,583 and KT 5823 ( figure 6 ).
Compound 22 also induced tyrosine phosphorylation of p42/p44 mapk , as determined by using an antibody directed against the tyrosine phosphorylated form of p42/p44 mapk . This effect was observed within 30 minutes of Compound 22 application (2.2±0.4-fold increase over control), and then decreased to basal level after 60 minutes. The stimulation observed after 30 minutes was abolished in cells pre-incubated with 10 mM PD 123,319 ( figure 7) .
In vivo assays
Intravenous doses of Compound 22 raised the duodenal alkaline secretion dose-dependently with a threshold for response at an infusion rate of 0.03 mg/Kg-1/h -1 . The secretory response to the highest dose was significantly inhibited by the AT 2 receptor antagonist PD 123,319 (0.3 mg/ Kg -1 /h -1 ) (figure 8, left panel). Compound 22 also stimulated secretion when exposed topically to the mucosa by administering it into the intraluminal perfusate at a concentration of 100 µM. In addition, this response was sensitive to PD 123,319 (150 mM intraluminally) (figure 8, right panel). Mean arterial pressure was not significantly As AT 2 receptor-related hypotensive effects have been reported, particularly in spontaneously hypertensive rats, 36 a limited number of experiments was performed in this rat strain. Basal mean arterial pressure before drug administration ranged between 158 to 203 mmHg (mean value 182 mmHg, n=41) and a wide dose range was studied (0.008 to 4 mg/kg intravenously). Compound 22 at low doses (0.008 and 0.05 mg/ kg) decreased mean arterial pressure; a response that was attenuated in animals treated with PD 123,319 (0.3 mg/Kg -1 /h -1 i.v.) ( figure 9 ). Changes in mean arterial pressure at the higher dose levels did not reach statistical significance as compared to vehicle. PD 123,319 had no intrinsic effect on mean arterial pressure.
Pharmacokinetics of Compound 22
The oral absorption study was performed on male Sprague-Dawley rats in triplicate with three oral concentrations (30 mg/kg, 100 mg/kg, 300 mg/kg) and one intravenously (30 mg/kg). An approximate dose-proportional increase in the systematic exposure of 22 was observed with increasing dose levels. Total clearance of 22 from plasma was nominally similar to hepatic plasma flow rate in rats. The apparent volume of distribution was up to 2.9-fold greater than total body water in rats, suggesting that 22 may be sequestered widely into the tissues. Plasma concentrations of 22 declined with apparent terminal half-lives ranging from three to six hours following oral administration. Following intravenous administration, plasma concentrations declined with apparent terminal half-lives of 0.5 to 2.5 hours. Estimates of absolute bioavailability of 22 following oral administration ranged from 20 to 30%. 
Conclusion
The non-selective AT 1 /AT 2 receptor compound L-162,313 was determined to act as an agonist on the AT 2 receptor. With this knowledge, we were able to use L-162,313 as a starting point for our medicinal chemistry programme to develop a selective non-peptide AT 2 receptor agonist. By stepwise modifications, we have been able to obtain the first drug-like selective AT 2 receptor agonist, Compound 22. Compound 22, with 20-30% oral bioavailability and a half-life estimated to four hours in the rat, mimics Ang II in its actions on the AT 2 receptor. Thus, Compound 22 induces outgrowth of neurite cells, enhances carbonate secretion from the rat intestine and lowers the mean arterial blood pressure in spontaneously hypertensive rats. We believe that Compound 22 will serve as a valuable research tool for studies of the function of the AT 2 receptor. Although long-term clinical studies are lacking, numerous experimental studies indicate that the clinical improvements observed following treatment with selective AT 1 receptor antagonists to a large extent are due to activation of the unopposed AT 2 receptor and increased plasma level of Ang II. 23 It follows that direct activation of AT 2 receptors during, e.g. hypertension and cardiovascular remodelling is an attractive pharmaceutical principle. The presently reported AT 2 receptor-selective agonist Compound 22 could possibly be regarded as a first member of such a novel drug class.
